Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a partial response, and ultimately all patients under...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cells
Главные авторы: Saltarella, Ilaria, Desantis, Vanessa, Melaccio, Assunta, Solimando, Antonio Giovanni, Lamanuzzi, Aurelia, Ria, Roberto, Storlazzi, Clelia Tiziana, Mariggiò, Maria Addolorata, Vacca, Angelo, Frassanito, Maria Antonia
Формат: Artigo
Язык:Inglês
Опубликовано: MDPI 2020
Предметы:
Review
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7017193/
https://ncbi.nlm.nih.gov/pubmed/31936617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9010167
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы